Last Updated : May 21, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort ascending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Fabrazyme | Agalsidase beta | Fabry Disease | Do not list | Complete | ||
Fabrazyme | Agalsidase beta | Fabry Disease | Do not list | Complete | ||
Eylea HD | aflibercept 8mg/0.07mL | macular degeneration, age related | Active | |||
Eylea HD | aflibercept 8mg/0.07mL | diabetic macular edema | Active | |||
Eylea | Aflibercept | Macular edema, branch retinal vein occlusion | Reimburse with clinical criteria and/or conditions | Complete | ||
Eylea | Aflibercept | Macular edema, diabetic | List with clinical criteria and/or conditions | Complete | ||
Eylea | Aflibercept | Macular edema, central retinal vein occlusion | List with clinical criteria and/or conditions | Complete | ||
Eylea | Aflibercept | Macular degeneration, age-related | List with criteria/condition | Complete | ||
Exjade | Deferasirox | Iron overload | List with clinical criteria and/or conditions | Complete | ||
Exelon Patch | Rivastigmine | Dementia (Alzheimer's type) | Do not list | Complete |